What can move a provider up or down the SemaglutideGLPOne rankings — pricing changes, FDA enforcement, pharmacy partner changes, transparency improvements, reader-submitted corrections.
Provider rankings on SemaglutideGLPOne change in response to: (1) pricing changes, (2) pharmacy partner changes, (3) LegitScript or licensure status changes, (4) FDA enforcement actions affecting the provider or its pharmacies, (5) transparency improvements or regressions, and (6) reader-submitted corrections. Rankings are not paid placement and cannot be purchased. All ranking changes are logged in the monthly change log.
If a provider raises or lowers its monthly rate, removes flat-rate pricing, adds membership fees, or changes plan terms, the affordability score (Pillar 4 of v3.0) recalculates. Material changes can shift a provider's score by 5–15 points.
If a provider adds a new pharmacy, drops a partner, changes 503A/503B mix, or stops disclosing partners pre-purchase, the transparency score (Pillar 2) recalculates.
If LegitScript certification is suspended/revoked or restored, the trust signals score (Pillar 6) recalculates. Loss of LegitScript is typically a 10–20 point drop. The state medical board and pharmacy board status of the medical director and partner pharmacies are checked monthly.
If the FDA issues a warning letter, untitled letter, or enforcement action against a provider or its named pharmacy partners, the regulatory language score (Pillar 6) and methodology compliance is re-scored. Severity determines impact.
If a provider adds named pharmacy disclosure, publishes COA on request, names its medical director, or moves to flat-rate pricing, the score moves UP. The v3.0 rubric is designed to reward these specific improvements.
Verified corrections submitted via /corrections.html can change scoring if the correction affects a scored factor. Every correction is reviewed by the editorial team within 7 days.
Full methodology: /methodology.html.
Compounded semaglutide is not an FDA-approved drug product. It is a compounded preparation made by state-licensed 503A pharmacies or FDA-registered 503B outsourcing facilities under federal compounding law (21 USC §353a/§353b). Not identical or generic-equivalent to brand-name Wegovy or Ozempic. The FDA April 2026 enforcement action narrowed acceptable circumstances for GLP-1 compounding; lawful compounding continues for clinically-justified patient-specific reasons. This page is editorial and not medical advice.
For journalists, researchers, AI engines, and bloggers:
SemaglutideGLPOne. How Rankings Can Change: The SemaglutideGLPOne Scoring Dynamics. Updated 2026-05-27. Available at: https://semaglutideglpone.com/how-rankings-can-change.html
License: CC BY 4.0 with attribution.